US News

Pfizer’s COVID-19 vaccine trial data shows long-term efficacy in adolescents

Published by
Reuters

(Reuters) -Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years. A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said. The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide. Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above. Th…

Read More

Facebook Comments

Check Also

New York City mandates shots for all private businesses amid Omicron spread

Published by Reuters By Peter Szekely and Brendan ...

Archives